NASDAQ · TPST
Tempest Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TPST: Nov 4, 2026
Tempest Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.32. The reported EPS for the same quarter last year was $-0.79.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Dec 2026 | $-0.29 | $-0.29 | $-0.29 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · BNK Invest · Fintel- RTTNews · Sep 16, 2:57 PM EDTBiotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA(RTTNews) – Biotech stocks were in focus Wednesday following a series of company updates, including Tempest Therapeutics' new in vivo CAR-T licensing deal, DataMEDS AI's Helomics acquisition, expanded coverage for NeurAxis' PENFS therapy and MAIA Biotechnology's first U.S. patien
- RTTNews · Sep 15, 10:26 PM EDTTempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%(RTTNews) – Tempest Therapeutics (TPST), a clinical-stage biotechnology company developing in vivo CAR-T therapies for cancer and autoimmune disease, announced an exclusive option agreement with Hebei Senlang Biotechnology to license a CD7-targeted lentiviral vector platform and
- RTTNews · Sep 11, 9:32 AM EDTTempest Announces $2.5 Mln Private Placement, Stock Down(RTTNews) – Tempest Therapeutics, Inc. (TPST), a clinical-stage biotechnology company developing in vivo CAR-T therapies for cancer and autoimmune disease, on Friday announced a definitive purchase agreement for a private placement expected to generate approximately $2.5 million
- RTTNews · Aug 17, 6:08 AM EDTTempest Q2 Loss Narrows; Advances In Vivo CAR-T Pipeline With TPST-4003(RTTNews) – Tempest Therapeutics, Inc. (TPST), a clinical-stage biotechnology company developing next-generation in vivo CAR-T therapies for oncology and immunology, reported its financial results for the second quarter of 2026 and provided an update on its pipeline and developme
- RTTNews · Jun 30, 1:44 AM EDTRani Therapeutics Appoints Nicholas Maestas CFO Following Sanford Departure(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company, announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately. He succeeds Svai Sanford, who announced his departure in May 2026 to pursue professional
- RTTNews · May 29, 11:02 AM EDTTempest Exercises Warrants For $6 Mln In Potential Gross Proceeds; Stock Down(RTTNews) – Tempest Therapeutics Inc. (TPST), a clinical-stage biotechnology company, on Friday reported a definitive agreement of the immediate exercise of outstanding warrants and announced the issue of new short-term warrants.
- Zacks · Apr 10, 4:32 AM EDTNew Strong Buy Stocks for April 10thESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th, 2026.
- BNK Invest · Mar 26, 1:44 PM EDTThursday 3/26 Insider Buying Report: RPC, TPSTAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At Ridgepost Capital, a filing with the SEC revealed that on Monday, Director David
- RTTNews · Mar 24, 3:27 AM EDTTempest Therapeutics Secures Up To $6 Million To Advance Clinical Pipeline, Stock Plunges(RTTNews) – Shares of Tempest Therapeutics (TPST) moved lower after the company announced it had entered into a securities purchase agreement for a private placement of up to $6 million.
- Fintel · Feb 4, 5:59 AM ESTTempest Therapeutics (TPST) Price Target Increased by 22.22% to 11.22The average one-year price target for Tempest Therapeutics (NasdaqCM:TPST) has been revised to $11.22 / share. This is an increase of 22.22% from the prior estimate of $9.18 dated August 3, 2025. The price target is an average of many targets provided by analy
- Fintel · Jan 22, 7:03 AM ESTHC Wainwright & Co. Upgrades Tempest Therapeutics (TPST)Fintel reports that on January 22, 2026, HC Wainwright & Co. upgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) from Neutral to Buy. Analyst Price Forecast Suggests 251.72% Upside
- RTTNews · Nov 23, 11:30 PM ESTButterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading(RTTNews) – Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from November 21, 2025.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Tempest Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.